Balance Sheet (Annual)

HVT / Haverty Furniture Companies, Inc. Balance Sheet shows account balances for the company at points in time. Balance Sheet data includes Assets, Current Assets, Fixed Assets, Property, Plant and Equipment (PPE), Inventory, Intangibles, Liabilities, Current Liabilities, Debt, Capital Lease Obligations, Common Stock, Retained Earnings, Treasury Stock, and Shareholders Equity.

All numbers are times 1,000 except per share units.

2011 2012 2013 2014 2015 2016 2017
Assets
  Assets Current
    Cash And Cash Equivalents At Carrying Value 49,585 53,550 83,185 65,481 70,659 63,481 79,491
    Restricted Cash And Cash Equivalents At Carrying Value 6,813 7,013 7,016 8,017 8,005 8,034 8,115
    Accounts Receivable Net Current 11,451 9,710 8,172 7,146 5,948 4,244 2,408
    Inventory Net 93,713 96,902 91,483 107,139 108,896 102,020 103,437
    Prepaid Expense Current 11,195 9,532 6,494 6,418 6,137 8,836 11,314
    Other Assets Current 4,918 3,187 4,349 8,010 6,341 7,500 5,922
    Assets Current 177,675 179,894 200,699 209,461 218,711 194,115 210,687
  Accounts Receivable Net Noncurrent 449 814 832 731 655 462 254
  Property Plant And Equipment Net 179,333 193,085 189,242 225,162 229,283 233,667 229,215
  Deferred Tax Assets Net Noncurrent 22,681 24,366 13,253 17,610 17,245 18,376 12,375
  Other Assets Noncurrent 4,962 3,937 13,829 8,023 5,357 7,885 8,798
  Assets 385,100 402,096 417,855 460,987 471,251 454,505 461,329
Liabilities And Stockholders Equity
  Liabilities Current
    Accounts Payable Current 18,233 28,178 21,810 24,152 27,815 25,662 20,501
    Contract With Customer Liability Current - - - - - - -
    Accrued Liabilities Current 32,171 33,272 36,338 39,960 42,060 41,904 37,582
    Capital Lease Obligations Current 762 881 959 2,387 3,051 3,461 3,788
    Liabilities Current 72,373 89,889 78,115 95,875 93,962 95,950 89,684
  Capital Lease Obligations Noncurrent 12,284 18,473 16,196 46,678 50,074 52,013 50,803
  Other Liabilities Noncurrent 37,774 34,306 25,280 26,351 25,476 24,671 26,700
  Liabilities 122,431 142,668 119,591 168,904 169,512 172,634 167,187
  Stockholders Equity
    Capital Stock
      Preferred Stock Value - - - - - - -
      Common Stock Value - - - - - - -
    Additional Paid In Capital 69,209 73,803 77,406 79,726 83,179 86,273 88,978
    Retained Earnings Accumulated Deficit 264,083 254,310 281,222 260,031 279,760 277,707 287,390
    Accumulated Other Comprehensive Income Loss Net Of Tax -24,996 -23,378 -15,412 -2,168 -1,938 -1,830 -2,144
    Treasury Stock Value 75,847 75,816 75,720 76,436 90,302 111,412 111,322
    Stockholders Equity 262,669 259,428 298,264 292,083 301,739 281,871 294,142
  Liabilities And Stockholders Equity 385,100 402,096 417,855 460,987 471,251 454,505 461,329

Peers - Furniture Stores (5712)

Related Articles

REPH: Recro Pharma Analysis and Research Report

2018-08-20 - Asif

Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...

ACHN: Achillion Pharmaceuticals Analysis and Research Report

2018-08-20 - Asif

Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...

BTE: Baytex Energy Trust Analysis and Research Report

2018-08-20 - Asif

General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...